Ingrid M.
- Country
- France
- Department
- Radio-oncologie
Research Overview
- Evaluation of Darolutamide Combined with Stereotactic Body Radiation Therapy in Castration-Resistant Prostate Cancer with Oligometastases Detected by Functional Imaging
- Evaluation of Darolutamide and Stereotactic Dose-Escalated Radiotherapy in High-Risk Localized Prostate Cancer: A Phase III Randomized Trial
- Phase II Evaluation of Sequential Gemcitabine and Paclitaxel Albumin-Bound Followed by FOLFIRINOX and MRI-Guided Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Data & Insights
Has run more than one trial at 28 of 88 partner sites.
Specializations
Pancreatic Cancer Treatment
This investigator specializes in developing innovative treatment approaches for locally advanced pancreatic adenocarcinoma, with particular focus on combination therapy strategies.
- Sequential chemotherapy protocols
- Advanced radiotherapy techniques
- Personalized treatment adaptation
The investigator's work encompasses the integration of MRI-guided adaptive radiotherapy with systematic chemotherapy approaches.
Therapeutic Innovation
Key research interests include the development of sequential treatment protocols combining different chemotherapy regimens for optimal patient outcomes.
- Multi-modal treatment strategies
- Chemotherapy sequencing
- Treatment response assessment
The investigator focuses on evaluating the effectiveness of combined chemotherapy and radiotherapy approaches in pancreatic cancer treatment.
Advanced Imaging Applications
Expertise in implementing MRI-guided therapeutic interventions for precise cancer treatment delivery and monitoring.
- Adaptive radiation therapy
- Image-guided treatment
- Therapeutic monitoring
The investigator employs advanced imaging techniques to enhance the accuracy and effectiveness of cancer treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.